---
title: "Weekly Recap | CVS Health -0.35%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301466257.md"
description: "CVS Health (CVS) fell 0.35% this week to $86.16, underperforming the S&P 500 by about 1.5 percentage points. Trading was choppy: the stock opened Monday at $86.69, pushed as high as $89.93 midweek, then pulled back into Friday’s close at $86.16 after touching $85.80 in the session low. Weekly amplitude was 5.08%, and daily volume ran about 40% above the stock’s own median."
datetime: "2026-10-10T06:26:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301466257.md)
  - [en](https://longbridge.com/en/news/301466257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301466257.md)
generator: "portal-rs"
---

# Weekly Recap | CVS Health -0.35%, most brokers rate it buy

## The Week

CVS Health (CVS) fell 0.35% this week to $86.16, underperforming the S&P 500 by about 1.5 percentage points. Trading was choppy: the stock opened Monday at $86.69, pushed as high as $89.93 midweek, then pulled back into Friday’s close at $86.16 after touching $85.80 in the session low. Weekly amplitude was 5.08%, and daily volume ran about 40% above the stock’s own median.

## Key Events

Medicare star ratings dominated the narrative. On Monday, Aetna and UnitedHealthcare were reported tightening their 2027 Medicare Advantage networks, and CVS confirmed an 11 November pre-market call for third-quarter results. Friday was the key session: after CMS released 2027 ratings, CVS said more than 69% of its Medicare Advantage members sit in plans rated 4 stars or higher, with Aetna calling the outcome a boost to confidence in returning to appropriate margins. TD Cowen, however, warned the same day that star-rating setbacks could pressure earnings, and CVS was down as much as 3.17% in pre-market trading. Elsewhere, the first pharmacy-focused store opened in the Boston area, MMR vaccine availability was flagged amid a measles outbreak, and a law firm announced an investigation into officers and directors.

## Analyst Ratings

Of 27 covering firms, 18 rate it buy and 7 rate it overweight, with 2 neutral and none at underweight or sell. The consensus rating is strong buy, with a consensus target of $115.76, roughly 34% above the current price. The target range of $103 to $145 points to wide disagreement. CVS ranks second among 53 companies in its healthcare services industry for analyst ratings.

## The Week Ahead

US CPI and core CPI land on Thursday, with markets watching the inflation path. Further out, CVS reports third-quarter results before the market opens on 4 November, with estimates at $1.29 earnings per share and $104.8bn revenue. Aetna’s margins and Medicare Advantage membership mix will be the clearest read on whether the ratings outcome translates into earnings.

## In Short

Broker sentiment leans strongly positive, with the consensus target about 34% above spot, while the stock trades below its 20-day average and large-lot flows turned net seller in the latest session. The star-rating update cuts both ways: it supports Aetna’s margin story but leaves the near-term earnings question open. The next signposts are the US inflation prints and the third-quarter report.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CVS.US](https://longbridge.com/en/quote/CVS.US.md)

## Related News & Research

- [CVS Agrees to $315 Million Settlement Over Alleged Illegal Opioid Prescriptions](https://longbridge.com/en/news/301843746.md)
- [CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS](https://longbridge.com/en/news/301447898.md)
- [Oracle Stocks Edge Up as $1 Billion Backs AI Partners](https://longbridge.com/en/news/302919901.md)
- [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md)
- [PRECIOUS-Gold steadies after three-month lows as oil rally fans inflation worries](https://longbridge.com/en/news/302878644.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**